Get the Stockscreener App
166.75
0.59%
-0.99
After Hours:
166.75
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Ligand Pharmaceuticals Inc stock is traded at $166.75, with a volume of 193.97K.
It is down -0.59% in the last 24 hours and up +23.38% over the past month.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
See More
Previous Close:
$167.74
Open:
$167.86
24h Volume:
193.97K
Relative Volume:
0.94
Market Cap:
$3.27B
Revenue:
$152.42M
Net Income/Loss:
$45.24M
P/E Ratio:
66.43
EPS:
2.51
Net Cash Flow:
$6.97M
1W Performance:
+3.12%
1M Performance:
+23.38%
6M Performance:
+44.48%
1Y Performance:
+61.66%
1-Day Range:
$166.07
$169.49
1-Week Range:
$160.80
$169.49
52-Week Range:
$93.58
$169.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Name
Ligand Pharmaceuticals Inc
Sector
Industry
Phone
858-550-7500
Address
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
166.75 | 3.27B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.12 | 101.77B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.38 | 60.12B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
452.00 | 59.45B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
750.78 | 44.90B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
341.80 | 35.07B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-25 | Initiated | Stifel | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-30-24 | Initiated | RBC Capital Mkts | Outperform |
| Apr-14-21 | Resumed | Stephens | Overweight |
| Feb-04-21 | Reiterated | H.C. Wainwright | Buy |
| Oct-06-20 | Initiated | Barclays | Overweight |
| Mar-24-20 | Downgrade | Argus | Buy → Hold |
| Mar-10-20 | Initiated | Guggenheim | Neutral |
| Feb-06-20 | Initiated | The Benchmark Company | Buy |
| Sep-19-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Jun-11-19 | Initiated | Barclays | Equal Weight |
| May-03-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-06-19 | Reiterated | H.C. Wainwright | Buy |
| Oct-29-18 | Upgrade | ROTH Capital | Neutral → Buy |
| Oct-02-18 | Reiterated | H.C. Wainwright | Buy |
| Sep-11-18 | Reiterated | Argus | Buy |
| Aug-17-18 | Initiated | Goldman | Neutral |
| Aug-08-18 | Downgrade | ROTH Capital | Buy → Neutral |
| Jun-21-18 | Initiated | Argus | Buy |
| Dec-27-17 | Reiterated | H.C. Wainwright | Buy |
| Sep-05-17 | Resumed | H.C. Wainwright | Buy |
| Oct-05-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-16 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-11-16 | Initiated | Sidoti | Buy |
| Mar-03-16 | Initiated | H.C. Wainwright | Buy |
View All
Ligand Pharmaceuticals Inc Stock (LGND) Latest News
What is the dividend yield of Ligand Pharmaceuticals Incorporated2025 Top Gainers & Weekly Breakout Opportunity Watchlist - beatles.ru
Is Ligand Pharmaceuticals Incorporated stock poised for growthPortfolio Risk Summary & Real-Time Market Trend Scan - Newser
Is Ligand Pharmaceuticals Incorporated stock bottoming outJuly 2025 Final Week & Real-Time Stock Price Movement Reports - Newser
Using data models to predict Ligand Pharmaceuticals Incorporated stock movement2025 Biggest Moves & Precise Entry and Exit Recommendations - Newser
Ligand Pharmaceuticals (LGND) director Kozarich sells $76k in stock By Investing.com - Investing.com Australia
Published on: 2025-09-05 14:36:20 - Newser
What is Ligand Pharmaceuticals Incorporated s revenue forecastMarket Growth Review & AI Powered Trade Plan Recommendations - خودرو بانک
Advanced analytics toolkit walkthrough for Ligand Pharmaceuticals IncorporatedJuly 2025 Movers & Smart Swing Trading Techniques - Newser
Can Ligand Pharmaceuticals Incorporated reach all time highs this yearWeekly Risk Report & AI Forecasted Stock Moves - خودرو بانک
Can Ligand Pharmaceuticals Incorporated withstand a market correctionRisk Management & Intraday High Probability Alerts - خودرو بانک
MACD Signals Flash Warning for Ligand Pharmaceuticals Incorporated StockJuly 2025 PreEarnings & Community Consensus Stock Picks - beatles.ru
Published on: 2025-09-05 01:53:48 - Newser
Will Ligand Pharmaceuticals Incorporated see short term momentum2025 Market Outlook & Weekly High Momentum Picks - Newser
What is Ligand Pharmaceuticals Incorporated’s TAM (Total Addressable Market)2025 Buyback Activity & Reliable Entry Point Trade Alerts - خودرو بانک
Is Ligand Pharmaceuticals Incorporated part of any major index2025 Performance Recap & Long-Term Safe Investment Plans - خودرو بانک
Insider Sell: John Kozarich Sells Shares of Ligand Pharmaceutica - GuruFocus
Is this a good reentry point in Ligand Pharmaceuticals IncorporatedTrade Analysis Report & Low Drawdown Investment Strategies - Newser
How to build a dashboard for Ligand Pharmaceuticals Incorporated stockJuly 2025 Analyst Calls & Community Trade Idea Sharing Platform - Newser
Ligand Pharmaceuticals (LGND) director Kozarich sells $76k in stock - Investing.com
Ligand Pharmaceuticals Director Sells 467 Shares Between $161.51 and $164.25/Share - AInvest
Volume spikes in Ligand Pharmaceuticals Incorporated stock – what they meanEntry Point & Real-Time Buy Signal Alerts - Newser
Published on: 2025-09-04 06:48:32 - Newser
Custom watchlist performance reports with Ligand Pharmaceuticals Incorporated2025 Growth vs Value & Free Risk Controlled Daily Trade Plans - Newser
Will Ligand Pharmaceuticals Incorporated continue its uptrendPortfolio Update Summary & Community Consensus Trade Alerts - Newser
Will Ligand Pharmaceuticals Incorporated outperform the market in YEAREarnings Growth Report & Weekly High Potential Stock Alerts - خودرو بانک
Using Python tools to backtest Ligand Pharmaceuticals Incorporated strategiesShare Buyback & Scalable Portfolio Growth Ideas - Newser
Oppenheimer Raises Ligand Pharmaceuticals (LGND) Price Target to $190 | LGND Stock News - GuruFocus
Real time pattern detection on Ligand Pharmaceuticals Incorporated stockWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating - MarketScreener
Can volume confirm reversal in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Verified Short-Term Trading Plans - Newser
Custom strategy builders for tracking Ligand Pharmaceuticals IncorporatedJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
Will earnings trigger a reversal in Ligand Pharmaceuticals Incorporated2025 Price Action Summary & Consistent Profit Focused Trading Strategies - Newser
Aug Levels: What is the next catalyst for Ligand Pharmaceuticals IncorporatedQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - خودرو بانک
LGND: Benchmark Raises Price Target to $175 Maintaining Buy Rati - GuruFocus
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Benchmark raises Ligand Pharma stock price target to $175 on strong earnings - Investing.com Canada
Ligand price target raised to $175 from $160 at Benchmark - TipRanks
Applying Wyckoff theory to Ligand Pharmaceuticals Incorporated stockMarket Rally & Weekly Market Pulse Updates - Newser
Is Ligand Pharmaceuticals Incorporated attractive for institutional investorsLong Setup & Short-Term Trading Opportunity Alerts - خودرو بانک
Can Ligand Pharmaceuticals Incorporated rally from current levelsProduct Launch & Short-Term Trading Opportunity Alerts - Newser
Ligand Pharmaceuticals Inc Stock (LGND) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.40%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):